


NS13001

Cat. No.:	HY-102070		
CAS No.:	1063331-94-1		
Molecular Formula:	C ₁₇ H ₁₆ ClN ₇		
Molecular Weight:	353.81		
Target:	Potassium Channel		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (282.64 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.8264 mL	14.1319 mL	28.2638 mL
		5 mM	0.5653 mL	2.8264 mL	5.6528 mL
10 mM		0.2826 mL	1.4132 mL	2.8264 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.83 mg/mL (2.35 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 0.83 mg/mL (2.35 mM); Suspended solution; Need ultrasonic				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.83 mg/mL (2.35 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	NS13001 is a potent, selective, orally active allosteric positive modulator of SK channels (small conductance calcium-activated potassium channels). The EC ₅₀ s are 1.8 and 0.14 μM for SK2 and SK3, respectively. NS13001 holds promise as a potential therapeutic agent for treatment of spinocerebellar ataxia type 2 (SCA2) and possibly other cerebellar ataxias ^[1] .
IC₅₀ & Target	EC ₅₀ : 1.8 μM (SK2), 0.14 μM (SK3) ^[1]

REFERENCES

[1]. Kasumu AW, et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol. 2012 Oct 26;19(10):1340-53.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA